Forest Laboratories, Inc.
909 Third Avenue
New York
New York
10022-4731
United States
Tel: 212-421-7850
Fax: 212-750-9152
Website: http://www.frx.com/
About Forest Laboratories, Inc.
Explore your potential. Discover the rewards.
At Forest Laboratories, we believe in the power of potential. As one of the fastest growing pharmaceutical companies, we are committed to developing a talented, diverse workforce where individuals can learn, achieve and grow.
Highly skilled scientific teams within our Forest Research Institute enable us to license compounds at virtually any stage—from preclinical development to products that are ready for FDA review—and then complete the development and regulatory work to successfully bring these new products to market. Our products, including Lexapro®, Namenda® and Benicar®, help treat a range of conditions such as depression, anxiety, Alzheimer’s disease and hypertension.
In addition to further developing our established therapeutic franchises (central nervous system, cardiovascular and respiratory), we are expanding the scope of our pipeline to address a wider range of health concerns that affect people every day, such as inflammation and pain. This growth is creating significant new career opportunities, and we invite energetic, skilled professionals to join Forest and contribute to our future success.
Employees are the engine of our rapid growth, and in return we offer the incentives and benefits for a healthy work/life balance.
For career opportunities on Long Island, New Jersey and NYC please visit: www.frx.com
Last Updated: 06-01-2006
404 articles about Forest Laboratories, Inc.
-
Forest Laboratories, Inc. Announces Publication In Lancet Of Pivotal Phase III Hypertension Trial Of The Fixed-Dose Combination Of Nebivolol/Valsartan
6/2/2014
-
Forest Laboratories, Inc. Commences Consent Solicitations To Eliminate Existing Registration Rights Obligations On Certain Of Its Senior Notes
5/22/2014
-
Actavis Offers To Guarantee Certain Forest Laboratories, Inc. Senior Notes In Connection With Forest Consent Solicitations
5/22/2014
-
Emeryville's Adamas Pharmaceuticals Bags $25 Million Milestone Payment From Forest Laboratories, Inc.
5/21/2014
-
Forest Laboratories, Inc. To Present Data About Aclidinium, Aclidinium/Formoterol Combination, And Roflumilast At The American Thoracic Society International Conference
5/19/2014
-
Actavis Announces Proposed Senior Leadership Team Effective Following Completion Of Forest Laboratories, Inc. Acquisition
5/14/2014
-
Former Forest Laboratories, Inc. GC Joins Lowenstein Sandler's Life Sciences Practice
5/5/2014
-
Forest Laboratories, Inc. To Present Data About Levomilnacipran And Vilazodone At The American Psychiatric Association 167th Annual Meeting
5/5/2014
-
Actavis And Forest Laboratories, Inc. Announce Effectiveness Of Registration Statement On Form S-4
5/5/2014
-
Ironwood Pharmaceuticals And Forest Laboratories, Inc. To Present Linaclotide Data At Digestive Disease Week® 2014
5/1/2014
-
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2014
4/29/2014
-
Forest Laboratories, Inc. Scores Furiex Pharmaceuticals, Inc. For $1.1 Billion Cash
4/28/2014
-
Forest Laboratories, Inc. Investor Conference Call Regarding Acquisition Of Furiex Pharmaceuticals, Inc. To Take Place At 9:30 AM EST
4/28/2014
-
Actavis And Forest Laboratories, Inc. Receive Federal Trade Commission Second Request Under Hart-Scott-Rodino
4/18/2014
-
Ironwood Pharmaceuticals And Forest Laboratories, Inc. Launch New Direct-To-Consumer Awareness Campaign For LINZESS®
4/10/2014
-
Forest Laboratories, Inc. And Almirall Provide Update On The Fixed Dose Combination Of Aclidinium And Formoterol In The U.S.
4/9/2014
-
Forest Laboratories, Inc. Sets Date And Conference Call For Fiscal 2014 Fourth Quarter Earnings
4/1/2014
-
Forest Laboratories, Inc., Gedeon Richter Ltd. Tout Positive Phase 2b Bipolar Depression Data
3/31/2014
-
Forest Laboratories, Inc., Gedeon Richter Ltd. Shows Off Positive Phase 2b Data For Cariprazine To Treat Depression
3/21/2014
-
Forest Laboratories, Inc. And Adamas Pharmaceuticals Announce Forest’s Submission Of New Drug Application For Memantine Extended Release And Donepezil Fixed-Dose Combination For Alzheimer’s Disease
3/4/2014